INS
INS encodes insulin, the primary anabolic hormone regulating glucose homeostasis, lipid metabolism, and growth. Mutations in INS cause neonatal diabetes and MODY10, while dysregulation of its signaling axis is the core driver of type 2 diabetes and metabolic syndrome.
Key Takeaways
- •INS encodes insulin, the master anabolic hormone essential for glucose homeostasis, lipid storage, and growth.
- •Secreted by pancreatic beta cells in response to elevated blood glucose and incretin hormones.
- •Loss of insulin production causes Type 1 Diabetes, while cellular resistance to its signaling defines Type 2 Diabetes.
- •Mutations in the INS gene itself can cause permanent neonatal diabetes (PNDM) or maturity-onset diabetes of the young (MODY).
Basic Information
- Gene Symbol
- INS
- Full Name
- Insulin
- Also Known As
- IDDM2ILPR
- Location
- 11p15.5
- Protein Type
- Peptide Hormone
- Protein Family
- Insulin/IGF Family
Related Isoforms
The insulin receptor, mediating all primary metabolic effects.
Structurally related growth factors with overlapping signaling.
Key SNPs
Tags the Class I/III VNTR alleles regulating INS expression in the thymus; strong association with Type 1 Diabetes risk.
Associated with altered INS transcription levels and susceptibility to Type 1 Diabetes.
Influences insulin expression in pancreatic beta cells and is linked to birth weight and T1D.
Associated with fasting insulin levels and insulin resistance traits.
Though technically ADRB2, often studied in haplotypes affecting insulin secretion dynamics.
Implicated in INS mRNA stability and associated with varying fasting glucose levels.
Overview
The INS gene encodes proinsulin, which is enzymatically cleaved in pancreatic beta cells to form the mature peptide hormone insulin and C-peptide. Insulin is the body’s primary anabolic hormone, orchestrating the storage of nutrients after a meal. It powerfully stimulates glucose uptake in skeletal muscle and adipose tissue, promotes glycogen and lipid synthesis, and inhibits hepatic glucose production and lipolysis.
Because insulin dictates the systemic switch from catabolism (fasting) to anabolism (fed state), dysfunction in its production or signaling leads to catastrophic metabolic consequences, manifesting as diabetes mellitus. Beyond glucose control, insulin acts as a survival and growth factor for many tissues.
Conceptual Model
A simplified mental model for the pathway:
Insulin is the metabolic master switch: when present, the body stores energy; when absent, it burns it.
Core Health Impacts
- • Glucose homeostasis: Maintains fasting and postprandial blood glucose within a narrow, safe range.
- • Ketoacidosis prevention: Prevents ketoacidosis by suppressing unrestricted lipolysis.
- • Muscle maintenance: Drives muscle hypertrophy and prevents protein breakdown.
- • Vascular function: Regulates vascular endothelial function and nitric oxide production.
- • Energy partitioning: Central to energy partitioning and fat storage in adipocytes.
Protein Domains
A-Chain & B-Chain
The mature active hormone consists of two peptide chains linked by two disulfide bonds. Proper folding in the ER is critical for receptor binding.
C-Peptide
Cleaved from proinsulin and co-secreted with insulin. It serves as a reliable clinical biomarker of endogenous beta-cell function.
Signal Peptide
A 24-amino acid sequence on preproinsulin that directs the nascent peptide into the rough endoplasmic reticulum.
Upstream Regulators
Glucose (via GLUT2/GCK) Activator
Primary secretagogue. Enters beta cells, undergoes glycolysis, raises ATP/ADP ratio, closing K-ATP channels to trigger exocytosis.
Incretins (GLP-1, GIP) Activator
Gut hormones that bind beta-cell receptors, increasing cAMP and potentiating glucose-stimulated insulin secretion (GSIS).
Amino Acids Activator
Leucine and Arginine directly stimulate insulin release or act synergistically with glucose to enhance secretion.
Vagal Input Activator
Acetylcholine release during the cephalic phase of digestion primes beta cells for insulin secretion.
Free Fatty Acids Activator
Acutely stimulate insulin secretion via GPR40/FFAR1, though chronic elevation impairs beta-cell function.
PDX1 & MafA Activator
Master transcription factors that drive INS gene transcription and maintain mature beta-cell identity.
Downstream Targets
Insulin Receptor (INSR) Activates
Direct binding partner; activation initiates IRS-1/2 phosphorylation and the PI3K/AKT signaling cascade.
IGF-1 Receptor (IGF1R) Activates
Can bind insulin at high concentrations, mediating growth and mitogenic effects.
GLUT4 Translocation Activates
Downstream of AKT, induces the movement of GLUT4 vesicles to the plasma membrane in muscle and adipose tissue.
Glycogen Synthase Activates
Activated via AKT-mediated inhibition of GSK3β, promoting glucose storage as glycogen.
FoxO Factors Inhibits
Inhibited (phosphorylated and exported from nucleus) by insulin/AKT, suppressing gluconeogenesis.
HSL Inhibits
Hormone-Sensitive Lipase is inhibited in adipocytes, suppressing lipolysis and promoting fat storage.
Role in Aging
The insulin/IGF-1 signaling (IIS) pathway is one of the most evolutionarily conserved regulators of aging. While essential for life and growth, persistent hyperinsulinemia accelerates aging phenotypes by locking cells into an anabolic state and suppressing maintenance pathways.
IIS Pathway Conservation
Mutations reducing insulin-like signaling extend lifespan across taxa (e.g., daf-2, chico, FIRKO mice). Reduced IIS is synonymous with increased longevity.
FOXO Suppression
High insulin drives AKT-mediated inhibition of FOXOs. Suppressed FOXO means lower expression of antioxidant enzymes, DNA repair, and autophagy.
mTOR Overactivation
Insulin is a potent activator of mTORC1. Chronic hyperinsulinemia keeps mTOR "on," driving senescence and inhibiting proteostasis (autophagy).
Accelerated Aging
Peripheral insulin resistance forces beta cells to secrete compensatory hyperinsulinemia, which accelerates cardiovascular aging and cancer risk.
AGEs Accumulation
When insulin signaling fails, chronic hyperglycemia leads to glycation of proteins, stiffening tissues and directly accelerating tissue aging.
Stem Cell Exhaustion
Excessive anabolic signaling via insulin/mTOR can drive premature activation and subsequent depletion of adult stem cell pools.
Disorders & Diseases
Type 1 Diabetes (T1D)
An autoimmune disease where T-cells destroy pancreatic beta cells, resulting in absolute insulin deficiency.
Type 2 Diabetes (T2D)
Characterized by peripheral insulin resistance followed by progressive beta-cell failure. Initially, INS expression is massively upregulated (hyperinsulinemia).
Neonatal Diabetes (PNDM)
Dominant missense mutations (like C96Y) cause proinsulin misfolding, triggering massive ER stress and beta-cell apoptosis in infancy.
MODY 10
Maturity-Onset Diabetes of the Young type 10 is caused by milder INS mutations, presenting as an autosomal dominant, progressive secretory defect.
Insulinoma
Rare neuroendocrine tumors that autonomously secrete massive amounts of insulin, leading to severe, life-threatening fasting hypoglycemia.
Interventions
Supplements
Trace mineral that may enhance insulin receptor sensitivity and signaling efficacy.
Antioxidant studied for its potential to improve peripheral insulin sensitivity.
Involved in cellular glucose metabolism; deficiency is linked to impaired insulin action.
Contains bioactive compounds that may mildly mimic insulin action or enhance its signaling.
Acts as a second messenger in insulin signaling; often used for insulin resistance in PCOS.
Lifestyle
Directly reduces the glycemic load and subsequent requirement for postprandial insulin secretion.
Enhances non-insulin-dependent glucose uptake in muscle and improves long-term sensitivity.
Increases skeletal muscle mass, creating a larger sink for insulin-stimulated glucose disposal.
Reduces visceral and ectopic fat, relieving lipotoxicity and restoring insulin sensitivity.
Adequate sleep prevents cortisol and sympathetic overdrive, which otherwise induce insulin resistance.
Medicines
Direct replacement therapy for absolute or relative insulin deficiency (e.g., glargine, lispro).
Close K-ATP channels in beta cells, forcing insulin secretion independent of glucose (e.g., glipizide).
Potentiate glucose-stimulated insulin secretion, suppress glucagon, and promote weight loss.
Decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity without increasing insulin.
Prolong the action of endogenous incretins, indirectly supporting sustained insulin release.
Lab Tests & Biomarkers
Genetic Testing
Targeted sequencing to detect pathogenic variants causing neonatal diabetes or MODY10.
Comprehensive panels (INS, KCNJ11, ABCC8) for infants presenting with hyperglycemia.
Activity Markers
Directly measures circulating hormone; high levels indicate resistance, very low indicate failure.
Cleaved 1:1 with insulin; the best measure of endogenous beta-cell secretory capacity.
Elevated ratio signifies beta-cell ER stress and predicts progression to T2D.
Metabolic Markers
The primary target variable controlled by basal insulin secretion.
Reflects 3-month average glucose exposure; the standard diagnostic test for diabetes.
Indices estimating systemic insulin resistance and beta-cell function.
Hormonal Interactions
Glucagon Primary Antagonist
Secreted by alpha cells; raises blood glucose by promoting glycogenolysis and gluconeogenesis.
Cortisol Counter-Regulatory
Stress hormone that induces systemic insulin resistance and promotes hepatic glucose output.
Epinephrine Acute Antagonist
Inhibits insulin secretion and stimulates rapid glycogen breakdown during fight-or-flight.
Growth Hormone Chronic Antagonist
Promotes growth but antagonizes insulin action on carbohydrate and lipid metabolism.
GLP-1 / GIP Potentiators (Incretins)
Gut hormones that amplify insulin secretion in response to oral nutrient ingestion.
Amylin Co-Secreted Partner
Co-secreted with insulin; slows gastric emptying and promotes satiety.
Deep Dive
Network Diagrams
Beta Cell Secretion Pathway
Thymic INS Expression and Tolerance
Biosynthesis and Secretory Dynamics
Insulin production is a massive bioenergetic commitment for the beta cell. It begins as preproinsulin, a single-chain precursor with a signal peptide that directs it to the rough ER. Upon entry into the ER, the signal peptide is cleaved, yielding proinsulin.
In the ER, proinsulin must fold correctly, establishing three critical disulfide bonds (two inter-chain, one intra-chain). This precise folding is highly susceptible to disruption by genetic mutations or generic ER stress. Correctly folded proinsulin transits to the Golgi and is packaged into secretory granules.
Within these maturing granules, prohormone convertases (PC1/3 and PC2) cleave proinsulin, removing the C-peptide and leaving the mature A and B chains linked by disulfide bonds. Insulin complexes with zinc, forming a crystalline hexamer that is stored until secretion is triggered.
Secretion is biphasic. The first phase is a rapid spike of pre-docked granules released within minutes of a glucose surge. The second phase is a sustained, slower release of newly recruited and synthesized granules. Loss of first-phase secretion is the earliest identifiable defect in the pathogenesis of Type 2 Diabetes.
Mutations and ER Stress: The Akita Paradigm
The mechanism of permanent neonatal diabetes caused by INS mutations was dramatically illuminated by the Akita mouse model. This mouse harbors a spontaneous Cys96Tyr mutation in the Ins2 gene, breaking a crucial disulfide bond.
Because the mutant proinsulin cannot fold correctly, it accumulates in the ER. The beta cell attempts to resolve this via the Unfolded Protein Response (UPR). However, because the mutant protein is continually transcribed, the UPR transitions from a protective response to an apoptotic one. The beta cell essentially works itself to death trying to process the defective hormone.
Humans with homologous mutations (e.g., C96Y) suffer the exact same fate: rapid, massive beta-cell apoptosis in infancy, presenting clinically as permanent neonatal diabetes.
Central Tolerance: Why the INS Promoter Determines Autoimmune Risk
While insulin is famously a pancreatic hormone, trace expression in the thymus is essential for survival. During immune system development, thymic medullary epithelial cells express peripheral antigens to “educate” maturing T-cells. T-cells that react too strongly to these self-antigens are deleted.
The INS promoter contains a Variable Number of Tandem Repeats (VNTR). Class I VNTR alleles drive high expression in the pancreas but very low expression in the thymus. Consequently, the immune system is poorly tolerized to insulin, leading to a high risk of autoimmune attack against beta cells (Type 1 Diabetes).
Conversely, Class III VNTR alleles drive lower pancreatic expression but robust thymic expression. The developing T-cells see plenty of insulin, resulting in strong central tolerance and profound protection against Type 1 Diabetes.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
First report of a human insulin mutation (Insulin Chicago) causing abnormal receptor binding and diabetes.
Provided the first complete nucleotide sequence of the human INS gene.
Established that dominant missense mutations in INS cause proinsulin misfolding, ER stress, and neonatal diabetes.
Linked the INS VNTR region to Type 1 Diabetes susceptibility (IDDM2 locus).
Demonstrated how INS expression in the thymus dictates central immune tolerance, explaining the T1D risk.
Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis
Identified recessive INS mutations causing a complete lack of insulin production without the ER stress typical of dominant mutations.